uniQure (NASDAQ:QURE) Trading 6.3% Higher – Here’s What Happened

uniQure N.V. (NASDAQ:QURE) traded up 6.3% during trading on Monday . The stock traded as high as $20.05 and last traded at $20.3370. 129,852 shares were traded during mid-day trading, a decline of 95% from the average session volume of 2,831,731 shares. The stock had previously closed at $19.13.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. Wall Street Zen raised uniQure from a “sell” rating to a “hold” rating in a report on Saturday, March 28th. Wells Fargo & Company raised uniQure from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $15.00 to $60.00 in a report on Monday, March 9th. Leerink Partners reissued an “outperform” rating and issued a $35.00 price objective on shares of uniQure in a report on Monday, March 2nd. Stifel Nicolaus set a $28.00 price objective on uniQure in a report on Tuesday. Finally, Cantor Fitzgerald reissued a “neutral” rating and issued a $9.00 price objective (down from $55.00) on shares of uniQure in a report on Monday, March 2nd. Ten investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, uniQure presently has a consensus rating of “Moderate Buy” and an average price target of $42.83.

uniQure Stock Performance

The company’s fifty day simple moving average is $16.67 and its two-hundred day simple moving average is $24.97. The company has a debt-to-equity ratio of 0.33, a quick ratio of 10.43 and a current ratio of 10.40. The stock has a market capitalization of $1.44 billion, a P/E ratio of -6.56 and a beta of 0.87.

uniQure (NASDAQ:QURE) last issued its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.88) by $0.03. The firm had revenue of $3.56 million during the quarter, compared to the consensus estimate of $5.24 million. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. As a group, equities analysts forecast that uniQure N.V. will post -3.6 EPS for the current year.

Insiders Place Their Bets

In other news, insider Jeannette Potts sold 3,412 shares of the business’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $9.06, for a total value of $30,912.72. Following the completion of the sale, the insider owned 138,483 shares of the company’s stock, valued at approximately $1,254,655.98. The trade was a 2.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Matthew C. Kapusta sold 14,581 shares of the company’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $9.06, for a total transaction of $132,103.86. Following the completion of the transaction, the chief executive officer owned 660,658 shares in the company, valued at $5,985,561.48. This trade represents a 2.16% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 49,396 shares of company stock worth $722,734 over the last three months. Insiders own 4.79% of the company’s stock.

Hedge Funds Weigh In On uniQure

Institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. grew its stake in shares of uniQure by 15.7% in the third quarter. Vanguard Group Inc. now owns 1,125,108 shares of the biotechnology company’s stock valued at $65,673,000 after acquiring an additional 152,417 shares in the last quarter. Aberdeen Group plc grew its stake in shares of uniQure by 25.1% in the fourth quarter. Aberdeen Group plc now owns 3,678,640 shares of the biotechnology company’s stock valued at $88,030,000 after acquiring an additional 738,897 shares in the last quarter. Quinn Opportunity Partners LLC acquired a new position in shares of uniQure in the third quarter valued at about $6,281,000. Farallon Capital Management LLC grew its stake in shares of uniQure by 3,935.7% in the third quarter. Farallon Capital Management LLC now owns 565,000 shares of the biotechnology company’s stock valued at $32,979,000 after acquiring an additional 551,000 shares in the last quarter. Finally, Darwin Global Management Ltd. acquired a new position in shares of uniQure in the third quarter valued at about $23,760,000. 78.83% of the stock is currently owned by institutional investors and hedge funds.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.